Researchers proposed polyamines as a new therapeutic strategy for Short QT Syndrome type 3, a genetic condition associated with short cardiac repolarization and sudden events. The reported approach centers on countering the arrhythmogenic mechanism tied to SQTS3 by targeting pathways influenced by polyamine biology.